Takeda Oncology Executive and Leadership Team

Marcelo Barretta, the Chief Financial Officer at Takeda Oncology, directs all financial operations and strategic fiscal planning. Barretta oversees budgeting, forecasting, and resource allocation, ensuring robust financial health for the oncology business unit. This leadership role involves managing investment strategies and optimizing financial performance to support the development and global distribution of Takeda Oncology's therapeutic agents. By meticulously analyzing market trends and financial data, Marcelo Barretta drives fiscal discipline and identifies opportunities for sustainable growth, directly impacting the company's capacity to deliver life-saving treatments to patients worldwide. Barretta's financial acumen underpins the unit's ability to fund critical research and development initiatives, securing long-term operational stability and market competitiveness.

Teresa Bitetti, the Global President, Oncology Business Unit at Takeda Oncology, leads the strategic direction and operational execution for the entire oncology portfolio. Bitetti oversees global commercial strategies, product development pipelines, and market access initiatives, driving Takeda Oncology's mission to deliver transformative cancer therapies. This executive position involves fostering innovation, building strong relationships with healthcare stakeholders, and ensuring the successful launch and sustained growth of oncology treatments worldwide. By championing patient-centric approaches and spearheading market expansion, Teresa Bitetti significantly influences the company's impact on global oncology care. Bitetti's leadership ensures that Takeda Oncology remains at the forefront of developing and providing critical therapies to patients facing cancer.

Rob Smith, the President at Takeda Oncology, directs overarching business strategies and operational frameworks for the oncology division. Smith oversees the integration of research, development, and commercial activities, ensuring alignment with Takeda Pharmaceutical's global objectives. This leadership role focuses on driving innovation, expanding market reach, and enhancing the company's contribution to cancer patient care. By cultivating a culture of scientific excellence and operational efficiency, Rob Smith guides the organization in its pursuit of developing and delivering groundbreaking oncology therapies. Smith's strategic vision is critical for navigating the complex landscape of cancer treatment and ensuring Takeda Oncology's continued success in addressing unmet medical needs globally.

Christophe Bianchi, the President at Takeda Oncology, spearheads strategic initiatives and operational excellence across key segments of the oncology business. Bianchi focuses on advancing the development and global commercialization of innovative cancer therapies, ensuring Takeda Oncology meets critical patient needs. This executive role involves fostering cross-functional collaboration, optimizing resource deployment, and driving market penetration for the company's therapeutic portfolio. By championing scientific advancement and patient-focused strategies, Christophe Bianchi contributes significantly to Takeda Oncology's mission of improving lives affected by cancer. Bianchi's leadership ensures the effective execution of strategies aimed at expanding access to vital oncology treatments worldwide.

Tawnee Friedrich, the Chief Of Staff, GMAO at Takeda Oncology, provides strategic operational support and drives key initiatives across the Global Medical Affairs and Oncology (GMAO) organization. Friedrich coordinates cross-functional projects, enhances operational efficiency, and ensures seamless execution of strategic plans. This role involves facilitating communication between senior leadership and operational teams, optimizing workflows, and implementing best practices to advance Takeda Oncology's mission. By streamlining processes and fostering collaboration, Tawnee Friedrich ensures that the GMAO functions effectively in supporting the development and delivery of oncology therapies. Friedrich's contributions are vital for aligning operational activities with the company's overarching goals of improving patient outcomes and expanding global access to innovative treatments.